Endothelin signaling in osteoblasts: Global genome view and implication of the calcineurin/NFAT pathway

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 253-261

  Van Sant, Charles ^a   Wang, Gang ^a   Anderson, Mark G ^a   Trask, Oscar J ^a   Lesniewski, Rick ^a   Semizarov, Dimitri ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; CALCINEURIN; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL STIMULATION; CONTROLLED STUDY; GENE ACTIVATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF; PROTEIN SECRETION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANNEXIN A5; CALCINEURIN; CELL DIFFERENTIATION; CELL NUCLEUS; CELL SURVIVAL; ENDOTHELINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME; HUMANS; MESENCHYMAL STEM CELLS; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 33846826885     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0574     Document Type: Article

References (57)

1. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
2. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
3. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
4. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
5. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954-9.
6. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003;97:779-84.
7. Wang D, Christensen K, Chawla K, et al. Isolation and characterization of MC3T3-1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 1999;14:893-903.
8. Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-15.
9. Narayanan K, Srinivas R, Peterson MC, et al. Transcriptional regulation of dentin matrix protein 1 by JunB and p300 during osteoblast differentiation. J Biol Chem 2004;279:44294-302.
10. Festuccia C, Bologna M, Gravina GL, et al. Osteoblast conditioned media contain TGF-β1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 1999;81:395-403.
11. Luo Q, Kang Q, Si W, et al. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 2004;279: 55958-68.
12. Fisher JL, Field CL, Zhou H, et al. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 2000;61:1-12.
13. Zheng Q, Tang ZY, Xue Q, et al. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000;126: 641-6.
14. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A 1990;87:7678-82.
15. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 1997;17:337-42.
16. George DJ, Halabi S, Shepard TF, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005;11:1815-20.
17. Benoy IH, Salgado R, Van Dam P, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-62.
18. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
19. de Leseleuc L, Denis F. Inhibition of apoptosis by Nur77 through NF-κB activity modulation. Cell Death Differ 2006;13:293-300.
20. Bras A, Albar JP, Leonardo E, de Buitrago GG, Martinez AC. Ceramide-induced cell death is independent of the Fas/Fas ligand pathway and is prevented by Nur77 overexpression in A20 B cells. Cell Death Differ 2000;7:262-71.
21. Suzuki S, Suzuki N, Mirtsos C, et al. Nur77 as a survival factor in tumor necrosis factor signaling. Proc Natl Acad Sci U S A 2003;100: 8276-80.
22. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci U S A 1990;87:2466-70.
23. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002; 109 Suppl:S67-79.
24. Jadlowiec J, Koch H, Zhang X, et al. Phosphophoryn regulates the gene expression and differentiation of NIH3T3, MC3T3-1, and human mesenchymal stem cells via the integrin/MAPK signaling pathway. J Biol Chem 2004;279:53323-30.
25. Rodriguez JP, Gonzalez M, Rios S, Cambiazo V. Cytoskeletal organization of human mesenchymal stem cells (MSC) changes during their osteogenic differentiation. J Cell Biochem 2004;93:721-31.
26. Chae HJ, Chae SW, Kang JS, et al. Dexamethasone suppresses tumor necrosis factor-α-induced apoptosis in osteoblasts: possible role for ceramide. Endocrinology 2000;141:2904-13.
27. Kim SW, Her SJ, Park SJ, et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-1 cells. Bone 2005;37:359-69.
28. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
29. Pucci B, Bellincampi L, Tafani M, et al. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Exp Cell Res 1999;252:134-43.
30. Chan WH, Wu HY, Chang WH. Dosage effects of curcumin on cell death types in a human osteoblast cell line. Food Chem Toxicol 2006;44: 1362-71.
31. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31:578-83.
32. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
33. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 1983;96:191-8.
34. Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999; 181:67-73.
35. Bagnato A, Salani D, Di Castro V, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 1999;59:720-7.
36. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A 1999;96:11496-500.
37. Bagnato A, Rosano L, Spinella F, et al. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004;64:1436-43.
38. Eberle J, Fecker LF, Orfanos CE, Geilen CC. Endothelin-1 decreases basic apoptotic rates in human melanoma cell lines. J Invest Dermatol 2002;119:549-55.
39. Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001;438:485-91.
40. von Schroeder HP, Veillette CJ, Payandeh J, Qureshi A, Heersche JN. Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone 2003;33:673-84.
41. Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 2001;7: 1654-60.
42. Buchholz M, Biebl A, Neesse A, et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res 2003;63:4945-51.
43. Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996;77:1079-88.
44. Bierie B, Moses HL. TGF-β and cancer. Cytokine Growth Factor Rev 2006;17:29-40.
45. Dalwadi H, Krysan K, Heuze-Vourc'h N, et al. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 2005; 11: 7674-82.
46. Kai H, Kitadai Y, Kodama M, et al. Involvement of proinflammatory cytokines IL-1β and IL-6 in progression of human gastric carcinoma. Anticancer Res 2005;25:709-13.
47. Sohara Y, Shimada H, Minkin C, et al. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res 2005;65:1129-35.
48. Oukka M, Ho IC, de la Brousse FC, et al. The transcription factor NFAT4 is involved in the generation and survival of T cells. Immunity 1998;9:295-304.
49. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005;7:631-7.
50. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 2002;103 Suppl 48:302-5S.
51. Shichiri M, Sedivy JM, Marumo F, Hirata Y. Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol Endocrinol 1998;12: 172-80.
52. Wu-Wong JR, Chiou WJ, Dickinson R, Opgenorth TJ. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J 1997; 328:733-7.
53. Shichiri M, Hirata Y, Nakajima T, et al. Endothelin-1 is an autocrine/ paracrine growth factor for human cancer cell lines. J Clin Invest 1991;87: 1867-71.
54. Hirata Y, Yoshimi H, Takata S, et al. Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 1988;154:868-75.
55. Sun L, Blair HC, Peng Y, et al. Calcineurin regulates bone formation by the osteoblast. Proc Natl Acad Sci U S A 2005;102:17130-5.
56. Koga T, Matsui Y, Asagiri M, et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005;11:880-5.
57. Kakita T, Hasegawa K, Iwai-Kanai E, et al. Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. Circ Res 2001;88:1239-46.